Illumina TruSight Tumor 170

Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only.


BioMérieux EMAG

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.